GlassScriptPhysician profile
Crystal Terry
NPI 1619761558
$833.48
in general payments reported to CMS, 2019-2025
19 companies · $833 in 2025
The $833 reported for 2025 was more than what 82% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $833.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $833.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $833.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $170.96 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $82.54 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $70.14 | 2025 | Caplyta |
| Medtronic, INC. | $65.13 | 2025 | Minimed 780g, Inceptiv |
| Corcept Therapeutics | $60.27 | 2025 | Korlym |
| Axsome Therapeutics, INC. | $55.78 | 2025 | Auvelity, Sunosi |
| Exact Sciences Corporation | $52.89 | 2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $50.49 | 2025 | Zepbound, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $44.26 | 2025 | Breztri, Airsupra |
| Organon LLC | $30.39 | 2025 | Nexplanon |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.90 | 2025 | Xifaxan |
| Neurocrine Biosciences, INC. | $17.56 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.77 | 2025 | |
| Glaxosmithkline, LLC. | $16.18 | 2025 | Trelegy Ellipta |
| Gilead Sciences, INC. | $16.17 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seqirus USA INC | $15.38 | 2025 | Flucelvax, Fluad |
| Verity Pharmaceuticals INC. | $15.08 | 2025 | Tlando |
| Pfizer INC. | $14.96 | 2025 | |
| Novo Nordisk INC | $14.63 | 2025 | Rybelsus, Ozempic |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Crystal Terry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.